Trial Profile

Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms READIT

17 Jun 2022 First Interim Results (n=103) presented at the 27th Congress of the European Haematology Association
17 Jun 2021 Interim results (n=70; as of Mar 2021) presented at the 26th Congress of the European Haematology Association
08 Oct 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com